Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Rating Reaffirmed by Wedbush
Wedbush reissued their buy rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research report sent to investors on Wednesday, AnalystRatings.com reports. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2019 earnings at ($0.75) EPS, Q4 2019 earnings at ($0.83) EPS, FY2019 earnings at ($3.54) EPS, Q1 2020 earnings at ($0.82) EPS, Q2 2020 earnings at ($0.91) EPS, Q3 2020 earnings at ($0.92) EPS, Q4 2020 earnings at ($0.95) EPS, FY2020 earnings at ($3.60) EPS, FY2021 earnings at ($3.79) EPS, FY2022 earnings at ($0.92) EPS and FY2023 earnings at $4.41 EPS.
“Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share.”,” the firm’s analyst wrote.
A number of other analysts have also commented on the company. JMP Securities lowered their price objective on Kiniksa Pharmaceuticals to $35.00 and set a market outperform rating for the company in a research report on Wednesday. They noted that the move was a valuation call. ValuEngine upgraded Kiniksa Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, July 4th. Five equities research analysts have rated the stock with a buy rating, Kiniksa Pharmaceuticals presently has a consensus rating of Buy and an average target price of $26.50.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.68) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.03. Equities analysts anticipate that Kiniksa Pharmaceuticals will post -3.47 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in Kiniksa Pharmaceuticals by 33.1% in the second quarter. JPMorgan Chase & Co. now owns 3,832 shares of the company’s stock worth $52,000 after purchasing an additional 952 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Kiniksa Pharmaceuticals by 1,131.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock worth $48,000 after buying an additional 2,467 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Kiniksa Pharmaceuticals by 20.5% during the fourth quarter. Bank of New York Mellon Corp now owns 20,570 shares of the company’s stock worth $578,000 after buying an additional 3,499 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Kiniksa Pharmaceuticals by 17.9% during the second quarter. Parametric Portfolio Associates LLC now owns 31,595 shares of the company’s stock worth $428,000 after buying an additional 4,787 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Kiniksa Pharmaceuticals by 61.2% during the first quarter. Rhumbline Advisers now owns 12,811 shares of the company’s stock worth $231,000 after buying an additional 4,862 shares during the last quarter. Hedge funds and other institutional investors own 29.79% of the company’s stock.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Read More: Why do company’s buyback their stock?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.